

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 Jul 2026

Investigating in vivo bioequivalence of Famotidine 40 mg/5 ml suspension manufactured by Omid Behboud Co.compared to innovator product

Protocol summary

Study aim

Investigating in vivo bioequivalence of Famotidine 40 mg/5 ml suspension

Design

The clinical trial has control and test groups with crossover, randomized design, without blinding. Twenty-four healthy volunteers will participate randomly in the study as two twelve-person study groups. Each volunteer will receive a single dose of drug in two periods. Therefore, each volunteer will be his own "Control". To randomly assign participants in two groups, the lottery method will be used.

Settings and conduct

After oral administration of 5 ml Famotidine suspension blood samples will be collected in predetermined time intervals up to 12 hours. The samples will be stored in freezer -4 degrees centigrade until analysis and sample quantitation. The concentration of drug in blood samples will be measured by liquid chromatography. The study will be performed in Tabriz University of Medical Sciences.

Participants/Inclusion and exclusion criteria

Inclusion criteria: General Health (in terms of Liver, Heart and Kidney), Age (18-59 years old) Exclusion criteria: Smoking, History of cardiovascular, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy.

Intervention groups

Intervention group will receive 5 mL oral dose of test product (Famotidine suspension of Omid Behboud Co.) and Control group will receive 5 mL of reference product (Famotidine suspension of Lupin Co.). Blood samples will be taken for 12 hours at the mentioned time points after drug administration and the plasma will be stored in freezer until analysis.

Main outcome variables

Drug plasma concentration

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210519051345N44**

Registration date: **2024-01-22, 1402/11/02**

Registration timing: **prospective**

Last update: **2024-01-22, 1402/11/02**

Update count: **0**

Registration date

2024-01-22, 1402/11/02

Registrant information

Name

Parvin Zakeri-Milani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3334 8801

Email address

pzakeri@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-02-04, 1402/11/15

Expected recruitment end date

2024-09-21, 1403/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigating in vivo bioequivalence of Famotidine 40 mg/5 ml suspension manufactured by Omid Behboud Co.compared to innovator product		Tabriz	
Public title		Province	
Bioequivalence study of Famotidine Suspension		East Azarbaijan	
Purpose		Postal code	
Other		51664-14766	
Inclusion/Exclusion criteria		Approval date	
Inclusion criteria:		2024-01-14, 1402/10/24	
General Health (in terms of Liver, Heart and Kidney), Age (18-59 years)		Ethics committee reference number	
Exclusion criteria:		IR.TBZMED.REC.1402.782	
Smoking, History of cardiovascular disease, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy		Health conditions studied	
Age		<u>1</u>	
From 18 years old to 59 years old		Description of health condition studied	
Gender		In the present study, the products will be administered to healthy volunteers	
Male		ICD-10 code	
Phase		ICD-10 code description	
Bioequivalence		Primary outcomes	
Groups that have been masked		<u>1</u>	
No information		Description	
Sample size		Plasma concentration of drug	
Target sample size: 24		Timepoint	
Randomization (investigator's opinion)		0.5-12 hours in predetermined time intervals after drug administration	
Randomized		Method of measurement	
Randomization description		HPLC (High performance liquid chromatography)	
To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.		Secondary outcomes	
Blinding (investigator's opinion)		empty	
Not blinded		Intervention groups	
Blinding description		<u>1</u>	
Placebo		Description	
Not used		Intervention group: Intervention group will receive 5 mL oral dose of test product (Famotidine suspension manufactured by Omid Behboud) in fasted state. Blood samples will be collected for 12 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours after drug administration, respectively	
Assignment		Category	
Crossover		Treatment - Drugs	
Other design features		<u>2</u>	
Secondary Ids		Description	
empty		Control group: Control group will receive 5 mL oral dose of reference product (Famotidine suspension manufactured by Fizer) in fasted state. Blood samples will be collected for 12 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be stored in freezer until analysis. Breakfast and lunch will be served two and six hours	
Ethics committees			
<u>1</u>			
Ethics committee			
Name of ethics committee			
Biomedical Research Committe, Tabriz University of Medical Sciences			
Street address			
No.2 Central Building 3rd Floor, Tabriz University of Medical Sciences, Daneshgah st.			
City			

after drug administration, respectively.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Faculty of Pharmacy, Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori st., Golgasht st.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parviz Shahabi

Street address

No.2 Central Building 3rd Floor, Daneshgah st. Tabriz University of Medical Science

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

shahabip@tbzmed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Omid Behboud Co.

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori street, Golgasht street

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori street, Golgasht street

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Attar Neishaboori street, Golgasht street

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Not applicable

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Not applicable

Data Dictionary

Not applicable